Group One Trading
ORKA

Group One Trading’s Oruka Therapeutics ORKA Stock Holding History

Group One Trading’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9K Sell
136
-64
-32% -$4.26K ﹤0.01% 6253
2026
Q1 		$9.81K Hold
200
– – ﹤0.01% 6387
2025
Q4 		$6.06K Buy
200
+100
+100% +$2.79K ﹤0.01% 7086
2025
Q3 		$1.92K Buy
+100
New +$1.48K ﹤0.01% 7909
2025
Q2 		– Sell
-2,108
Closed -$22K – 8800
2025
Q1 		$21.6K Buy
2,108
+2,085
+9,065% +$26K ﹤0.01% 5768
2024
Q4 		$446 Buy
+23
New +$561 ﹤0.01% 7011
2024
Q3 		– Sell
-594
Closed -$20.7K – 7503
2024
Q2 		$27.3K Buy
+594
New +$23.7K ﹤0.01% 4993
2023
Q2 		– Sell
-1,917
Closed -$45.8K – 8301
2023
Q1 		$45.8K Buy
+1,917
New +$50.5K ﹤0.01% 4916
2022
Q4 		– Sell
-12,024
Closed -$308K – 8236
2022
Q3 		$297K Buy
12,024
+1,066
+10% +$30.1K ﹤0.01% 3754
2022
Q2 		$327K Buy
+10,958
New +$310K ﹤0.01% 3837
2021
Q2 		– Sell
-181
Closed -$7.55K – 8652
2021
Q1 		$8K Buy
+181
New +$9.5K ﹤0.01% 7136

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Group One Trading's ORKA Position: Q2 2026 in Review

Group One Trading reduced its Oruka Therapeutics (ORKA) stake by 32% in Q2 2026, selling an estimated $4.26K and leaving 136 shares worth $12.9K. The position accounts for ﹤0.01% of the portfolio, ranked #6253.

Group One Trading first reported a position in ORKA in Q1 2021 and has held it in 11 quarters since. The position peaked at $327K in Q2 2022. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Group One Trading held 136 shares of Oruka Therapeutics worth $12.9K as of Q2 2026.
  • Group One Trading sold 64 Oruka Therapeutics shares in Q2 2026, an estimated $4.26K.
  • Oruka Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #6253 holding.
  • Group One Trading first reported a position in Oruka Therapeutics in Q1 2021 and has held it in 11 quarters since.
  • Group One Trading's Oruka Therapeutics position peaked at $327K in Q2 2022.
  • 256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.